Merck (MRK): ABN AMRO Bank N.V. reduced its stake -1.73M shares
ABN AMRO Bank N.V. reduced its stake in Merck, per its Q4 2025 13F.
- 192K
- Shares reported · -1.73M vs prior quarter
- 0.19%
- Disclosed portfolio weight
- $20.2M
- Reported value
- Holdings as of
- Dec 31, 2025
- Filed
- Feb 4, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 13, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
- Nov 18, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
- Dec 12, 2025FDARecall: Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured…
- Dec 12, 2025FDARecall: Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp & Doohme LLC, Rahway…
- Dec 18, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
- Dec 19, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
- Jan 13, 2026Federal contract · $96K obligatedDepartment of Veterans Affairs awarded Merck: $96K obligated to date
- Jan 27, 2026FDAFDA drug approval: Noxafil
- Jan 27, 2026FDAFDA drug approval: Noxafil
- Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
- Feb 4, 2026Insider · 4 peopleInsiders: 6 sales (~$13.2M)
- Feb 4, 2026CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
What came next
- Feb 5, 2026InsiderOfficer sold ~$2.44M of MRK shares in the open market
- Feb 6, 2026Insider · 3 peopleInsiders: 3 sales (~$7.0M)
- Feb 9, 2026Insider · 2 peopleInsiders: 4 sales (~$15.7M)
- Feb 10, 2026FDAFDA drug approval: Keytruda
- Feb 10, 2026FDAFDA drug approval: Keytruda Qlex
- Feb 10, 2026InsiderOfficer sold ~$1.2M of MRK shares in the open market
- Feb 12, 2026InsiderOfficer sold ~$1.21M of MRK shares in the open market
- Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Apr 15, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
- Apr 24, 2026FDAFDA drug approval: Keytruda Qlex
- Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- May 4, 2026Federal contract · $43K obligatedDepartment of Veterans Affairs awarded Merck: $43K obligated to date
- May 8, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
- May 11, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
- May 11, 2026Federal contract · $342K obligatedDepartment of Veterans Affairs awarded Merck: $342K obligated to date
- May 21, 2026Federal contract · $23K obligatedDepartment of Veterans Affairs awarded Merck: $23K obligated to date
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Merck
For Merck, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 3 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.
How this filing works
Explore the data
Common questions
What does this filing report about Merck (MRK) stock?
ABN AMRO Bank N.V. reduced its stake in Merck, per its Q4 2025 13F. Now 192K shares, $20.2M reported value, 0.19% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Dec 31, 2025. Filed: Feb 4, 2026.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Merck recently?
For Merck, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 3 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days. They are listed on the MRK page.
Does this mean MRK stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Merck
- SEC Form 4Nov 16, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 144Nov 12, 2026
- SEC Form 144Nov 2, 2026
- House Clerk periodic transaction reportOct 7, 2026
- USAspending.gov award recordSep 24, 2026
Everything OQRO holds on this company is on its MRK page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
